Byotrol (LSE:BYOT) ROCE % : -22.19% (As of Sep. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Byotrol ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Byotrol's annualized ROCE % for the quarter that ended in Sep. 2023 was -22.19%.

Byotrol ROCE % Historical Data

The historical data trend for Byotrol's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Byotrol ROCE % Chart

Byotrol Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

6.87

4.07

13.53

-15.31

-24.39

Byotrol Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
ROCE %	Get a 7-Day Free Trial															-3.16	-26.87	-15.46	-30.86	-22.19

Byotrol ROCE % Calculation

Byotrol's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-1.754	/	( ( (8.771 - 1.258)	+	(7.741 - 0.871) )	/ 2 )
	=	-1.754	/	( (7.513	+	6.87)	/ 2 )
	=	-1.754	/	7.1915
	=	-24.39 %

Byotrol's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	-1.44	/	( ( (7.741 - 0.871)	+	(7.134 - 1.024) )	/ 2 )
	=	-1.44	/	( ( 6.87	+	6.11 )	/ 2 )
	=	-1.44	/	6.49
	=	-22.19 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

Byotrol (LSE:BYOT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Byotrol ROCE % Related Terms

Thank you for viewing the detailed overview of Byotrol's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Byotrol (LSE:BYOT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Byotrol PLC (LSE:BYOT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

B7Y:Germany

Address

Building 303 (Ashton), Pool Lane, Thornton Science Park, Ince, Chester, GBR, CH2 4NU

Website

https://www.byotrolplc.com

Byotrol PLC is a developer of consumer and professional antimicrobial technologies and products. It is engaged in the development, patenting, licensing, and sale of anti-microbial products and technologies for business and consumer use. It operates in two reportable segments, being Professional (including Human Health, Animal Health, Facilities Management, and Food & Beverage), and Consumer (Including Household, Skin Care, and Pet Care). Its customers are based in the UK, North America, Asia, and the Rest of the World. The company generates key revenue from product sales - sale of anti-microbial technology and includes Royalty and licensing income.

Byotrol (LSE:BYOT) Headlines

No Headlines